^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FPI-1966

    i
    Other names: FPI-1966, [225Ac]-FPI-1966, actinium Ac 225 vofatamab, actinium-225 vofatamab, [225Ac]-vofatamab
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    FGFR3 inhibitor, Alpha radiation emitter
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=6, Terminated, Fusion Pharmaceuticals Inc. | Completed --> Terminated; Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.
    Trial termination • Metastases
    |
    vofatamab (B-701) • FPI-1966
    1year
    A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=6, Completed, Fusion Pharmaceuticals Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2023 | Trial primary completion date: Jun 2026 --> Sep 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    vofatamab (B-701) • FPI-1966
    over1year
    A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, Fusion Pharmaceuticals Inc. | Recruiting --> Active, not recruiting | N=155 --> 6
    Enrollment closed • Enrollment change • Metastases
    |
    vofatamab (B-701) • FPI-1966